复制子
生物安全
严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)
2019年冠状病毒病(COVID-19)
病毒学
2019-20冠状病毒爆发
计算生物学
生物
病毒复制
病毒
大流行
医学
生物技术
传染病(医学专业)
质粒
遗传学
基因
爆发
病理
疾病
作者
Xi He,Shuo Quan,Min Xu,Silveria Rodriguez,Shih Lin Goh,Jiajie Wei,Arthur Fridman,Kenneth A. Koeplinger,Steve Carroll,Jay A. Grobler,Amy S. Espeseth,David B. Olsen,Daria J. Hazuda,Dai Wang
标识
DOI:10.1073/pnas.2025866118
摘要
Significance The urgency of curbing the COVID-19 pandemic has motivated many investigators to pivot their research to understand the basic biology of SARS-CoV-2 and to search for new pharmaceutical compounds for potential COVID-19 treatment. However, most SARS-CoV-2 studies require biosafety level 3 facilities, which are in high demand, costly, and difficult to access. To overcome these limitations, we engineered a SARS-CoV-2 replicon, which is a modified virus subgenome capable of self-replicating without producing infectious virus, allowing the viral replication to be studied in a conventional biomedical laboratory setting. The replicon system also provides a valuable tool to screen and test antiviral compounds in biologically relevant cells. Successful implementation of the technology will accelerate the development of effective treatment for SARS-CoV-2 infection.
科研通智能强力驱动
Strongly Powered by AbleSci AI